Trials / Unknown
UnknownNCT05861128
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
An Open-Label, Multicenter, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib | Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks |
Timeline
- Start date
- 2023-11-10
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2023-05-16
- Last updated
- 2024-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05861128. Inclusion in this directory is not an endorsement.